DS
VRDN icon

David Shaw’s Viridian Therapeutics VRDN Stock Holding History

David Shaw’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.7M Sell
1,182,222
-80,318
-6% -$1.29M 0.01% 1238
2026
Q1 		$24.7M Buy
1,262,540
+261,823
+26% +$7.78M 0.01% 1019
2025
Q4 		$31.1M Buy
+1,000,717
New +$27.4M 0.02% 974
2025
Q2 		– Sell
-81,383
Closed -$1.1M – 4743
2025
Q1 		$1.1M Sell
81,383
-360,687
-82% -$6.14M ﹤0.01% 3029
2024
Q4 		$8.47M Buy
442,070
+304,003
+220% +$6.61M 0.01% 1608
2024
Q3 		$3.14M Buy
+138,067
New +$2.26M ﹤0.01% 2341
2023
Q1 		– Sell
-338,167
Closed -$9.88M – 4902
2022
Q4 		$9.88M Sell
338,167
-290,108
-46% -$6.68M 0.01% 1438
2022
Q3 		$12.9M Sell
628,275
-130,853
-17% -$2.35M 0.02% 1153
2022
Q2 		$8.78M Sell
759,128
-23,967
-3% -$322K 0.01% 1512
2022
Q1 		$14.5M Buy
783,095
+18,482
+2% +$355K 0.01% 1279
2021
Q4 		$15.1M Buy
764,613
+44,083
+6% +$821K 0.01% 1298
2021
Q3 		$11.9M Buy
720,530
+157
+0% +$2.3K 0.01% 1383
2021
Q2 		$13.2M Buy
720,373
+531,861
+282% +$9.1M 0.01% 1281
2021
Q1 		$3.15M Buy
+188,512
New +$3.53M ﹤0.01% 2200
2019
Q4 		– Sell
-1,127
Closed -$12K – 4196
2019
Q3 		$12K Sell
1,127
-1,769
-61% -$39.1K ﹤0.01% 3762
2019
Q2 		$89K Sell
2,896
-2,814
-49% -$113K ﹤0.01% 3556
2019
Q1 		$239K Buy
5,710
+1,770
+45% +$80.1K ﹤0.01% 3324
2018
Q4 		$179K Buy
+3,940
New +$228K ﹤0.01% 3566

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

David Shaw's VRDN Position: Q2 2026 in Review

David Shaw reduced its Viridian Therapeutics (VRDN) stake by 6.4% in Q2 2026, selling an estimated $1.29M and leaving 1,182,222 shares worth $21.7M. The position accounts for 0.01% of the portfolio, ranked #1238.

David Shaw first reported a position in VRDN in Q4 2018 and has held it in 18 quarters since. The position peaked at $31.1M in Q4 2025. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • David Shaw held 1,182,222 shares of Viridian Therapeutics worth $21.7M as of Q2 2026.
  • David Shaw sold 80,318 Viridian Therapeutics shares in Q2 2026, an estimated $1.29M.
  • Viridian Therapeutics made up 0.01% of David Shaw's portfolio in Q2 2026, its #1238 holding.
  • David Shaw first reported a position in Viridian Therapeutics in Q4 2018 and has held it in 18 quarters since.
  • David Shaw's Viridian Therapeutics position peaked at $31.1M in Q4 2025.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.